Tempus AI, Inc. (TEM) Earnings Call Transcript & Summary

May 6, 2025

NASDAQ US Health Care Life Sciences Tools and Services earnings 36 min

Earnings Call Speaker Segments

Liz Krutoholow

executive
#1

Thanks, everyone. Hello, and thanks for joining us for Tempus' First Quarter 2025 Conference Call this afternoon. Earlier today, Tempus reported its results for the quarter that closed on March 31st, 2025. You can find the press release, a quarter overview, and our newest presentation on our IR website. With me today from Tempus are Eric Lefkofsky, our Founder and CEO, and Jim Rogers, our CFO. Before we get started, I want to note that management might make forward-looking statements on this call, and those statements carry risks and uncertainties that could make actual results differ materially. For a discussion of those risks, please see our 10-K and our other filings with the SEC. On this call, we'll also talk about non-GAAP financial measures, which aren't prepared in accordance with generally accepted accounting principles. You can find definitions of these non-GAAP financial measures, plus reconciliations to the most directly comparable GAAP financial measures, in our First Quarter Earnings release, which we've furnished to the SEC and which is available on our website at investors.tempus.com. I'd now like to hand the call over to Eric.

Eric Lefkofsky

executive
#2

Thanks. Appreciate everyone being here today. Tempus had a record Q1, and we're off to a great start. I'll give just a very quick overview, and then we can take questions. Quarterly revenue rose 75.4% year-over-year, reaching $255.7 million. Genomics revenue came in at $193.8 million, which represents roughly 89% growth year over year. Oncology testing — that's what we'll call our legacy Tempus clinical testing — was up 31% year-over-year, with volume growth of approximately 20%. Hereditary testing — our name for the legacy Ambry Genetics business — brought in $63.5 million in revenue and increased its units by 23%. Data and services revenue came to $61.9 million, up about 43% year-over-year, driven by our insights, or data licensing, business, which rose 58% year-over-year. We produced $155.2 million in gross profit for the quarter, which was 99.8% growth year-over-year. Adjusted EBITDA was negative $16.2 million in Q1 2025, versus negative $43.9 million in Q1 2024 — a $27.8 million improvement year-over-year. Because of that, we're raising our full year 2025 revenue guidance to $1.25 billion, which implies roughly 80% growth year-over-year. All in all, I'd say the company is performing extremely well, as my quote said. Revenues are up, gross profit is up. Both are growing nicely; we're keeping costs in check, which is delivering nice year-over-year operating leverage. I'll also call out one other big piece of news that we released about a week ago: we announced a three-year, $200 million data and modeling license agreement with AstraZeneca and Pathos in April to build the world's largest foundation model in oncology; this matters for a few reasons. First, it lifts our total remaining contract value to more than $1 billion as of April 30th; it also lets us take our over 300 PB of data — including this really rich multimodal data set tied to outcomes — and use it to build a foundation model, which, beyond the data licensing, is quite positive for us; on top of that, compute isn't cheap, and AZ and Pathos are covering a significant portion of that cost. Once the model is done — we expect the first version to be finished in about nine to 12 months — each party gets a copy: AstraZeneca and Pathos to push their drug discovery efforts forward, and Tempus to push its diagnostic and data products forward. Since AstraZeneca is our longest standing client — in fact, our first strategic collaboration — we couldn't be more excited to expand our relationship in such a significant way. I think it further validates the value we deliver to lots of biopharma clients. It's also worth noting this agreement is non-exclusive. Data licensing and joint model development with other parties are things we can do, and doing so down the road is our hope. That makes this a completely new category as far as we're concerned. Another reason it matters: it marks a huge leap toward turning precision medicine into something real. Our grasp of the molecular reasons behind why cancer therapies work for some patients and not others has never been better; insights of all sorts will, we believe, be brought sharply into view by models such as this one; a future is imaginable in which our diagnostics are intelligent enough to genuinely serve a vital function in keeping each patient on the best possible treatment course, and in which pharmaceutical firms operate much more efficiently, with clinical trials that fail much less frequently — in an ideal world, that is. With that said, we'd be glad to take your questions.

Tejas Savant

analyst
#3

Hello, everyone. Good evening, and I appreciate you all taking the time. Eric, congrats, and nice to see a solid beginning to the year. I have a question with two parts regarding the AZ/Pathos transaction you mentioned earlier. To start, could you share any details on ongoing discussions with additional pharmaceutical firms regarding potential comparable arrangements focused on building foundational models in oncology? What specifically about the Pathos methodology makes it so appealing to drugmakers? Regarding the transaction itself, this one's for Jim. I'd like to explore the way this deal has been put together. It comes across as somewhat intricate. Regarding how revenue recognition works for that $200 million, you've got the $50 million initial payment coming from Pathos to your side, yet you're simultaneously sending roughly $35 million back their way. On the upfront side, AZ is also handing over about $35 million, if I'm not mistaken. Could you walk us through what you anticipate happening on the P&L, plus that remaining $150 million from Pathos? My understanding is equity is part of that too. Give us a bit more detail on how it plays out across the coming three years and moves through the P&L. Thanks.

Eric Lefkofsky

executive
#4

Yeah, I can kick things off, and then Jim can chime in. After we made this announcement, there was clearly a lot of buzz among other companies. We collaborate with, I believe, 19 or 20 of the biggest pharma companies in oncology, and we've got solid relationships with many of them. A lot of people were really curious. AstraZeneca ranks among the top players in oncology and has built an impressive track record over the last four or five years. I think what everyone was especially eager to understand was what this would mean for them down the road and how they ought to incorporate it into their own operations. A few of those discussions are already underway. The level of enthusiasm exceeded my predictions. My hopes were already quite high, so this is fantastic; as Jim will explain shortly, these are major agreements. We're talking about $200 million in data licensing and actual data revenue. For a commitment of that size, a party must be genuinely convinced—it's a costly undertaking. Despite all the buzz, our job is to convert it into concrete contracts and concrete initiatives and get them underway. Regarding AZ and Pathos, AstraZeneca had previously been one of our customers. They had also invested time with Pathos and became acquainted with that group. Setting aside anything to do with Tempus, my sense is that they had been kicking around a few different concepts with one another. If you go back to the point when conversations about this foundation model idea first got underway, it made sense to expect that a three-party setup would be their preference — one in which they could commit a meaningful sum and contribute specific strengths of theirs, while at the same time benefiting from a great deal of work Pathos had already finished and, obviously, benefiting from our data along with all the things we had developed. The result was a structure built around three partners, even though it might equally well have taken the form of a two-way partnership with just our company and the pharma company, excluding Pathos. Jim is going to take you through the rev rec.

Jim Rogers

executive
#5

When it comes to how we recognize revenue, the simplest framing is this: there's a data license with Pathos worth $200 million, and it's tied specifically to the development of the foundational models. That data is restricted to that single use case, as AZ, Pathos, and Tempus collaborate on creating that foundational model. Certain cash movements occur from AZ to Tempus and then on to Pathos, yet none of that has any effect on revenue recognition. That $200 million is going to be recognized. It builds gradually across the three-year window, though it's essentially recognized evenly over that three-year term while the model gets built. This license works just like our other big subscriptions. No revenue gets recognized when Pathos makes its upfront payment to Tempus. It's a subscription spanning three years, comparable to the other sizable multi-year arrangements we have in place right now.

Eric Lefkofsky

executive
#6

Right. And then there's one final point there. That initial payment came through as cash. Now, while it's possible Pathos might choose to pay some amounts down the road using a mix of cash and stock, we've got every reason to believe cash is what they'll use. There's a strong chance we simply end up receiving cash for the whole duration.

Ryan MacDonald

analyst
#7

Appreciate you fielding my questions. Nice work on a strong quarter. Could you perhaps discuss the hereditary segment? My understanding is that when Ambry was folded in, the initial outlook pointed to something like a mid to high teens increase for the year, yet clearly we've started off at a notably quicker pace, roughly 23%. Would you be able to explain what came in better than anticipated regarding how that unit performed, and also how sustainable that roughly mid-20s expansion pace might be? Thanks.

Eric Lefkofsky

executive
#8

Yes. Clearly it's still early, so we shouldn't get too far ahead of ourselves. I believe we addressed this back when we shared news of the Ambry purchase — there existed a certain story that hereditary screening had either reached its twilight or sunset stage, or else turned into a commodity; our conviction is obviously the opposite, that such a view is simply wrong. I could picture a future where tens of millions of individuals receive this type of sequencing routinely, not only for knowing their inherited cancer risk, but also their inherited cardio risk, their inherited Alzheimer's risk, and their inherited risk of developing an immunological disorder later in life. The pool of people who might face disease risk is clearly far larger than the pool of people who actually have disease, broadly speaking. Over the long run, our belief is Ambry will expand at elevated rates. For the near term, we communicated that we expected growth to land in the mid to high teens. Mostly because they had gone through a stretch of very fast growth before, so you're now comparing against that stretch. Indeed, the business is doing very well; that could keep going, but our purpose here isn't to call attention to that for everyone. We're monitoring it month to month, yet thus far they're operating at full capacity and we detect nothing indicating a slowdown.

Mark Schappel

analyst
#9

Good evening, and thanks for taking my question — nice work this quarter. Eric, I wanted to ask about the Deep 6 acquisition you completed during the quarter. Could you share a bit more detail on which capabilities Deep 6 adds that you didn't already possess?

Eric Lefkofsky

executive
#10

Right. I think we discussed this too last quarter — we had the feeling that our molecular menu was already quite complete, and once Ambry came on board, we were pretty confident that across MRD, therapy selection, and now hereditary testing, we were in a strong spot, and that any future deals would probably be smaller and probably in data and services; and that, incidentally, describes Deep 6 precisely. Naturally, at the heart of how we operate is bringing together huge volumes of clinical and molecular information and creating these very rich data sets in which you can see at a molecular level what is going on with a patient and then tie those rich molecular insights to outcome and response information across time and say, "All right, if this is the molecular makeup of this patient — the DNA profile, the RNA profile, the germline profile, the methylomic profile — this is the patient's molecular profile. Which drugs did they receive? How did they respond? What adverse events occurred? How long did they stay on that drug? What was their progression-free survival? What was their overall survival?" All of that clinical information. To extract that clinical data, you need rich connections. We noted this quarter as well that we now have more than 4,000 connections, a significant increase over where we were before. Deep 6 contributes to adding more connectivity, particularly with some truly high-quality institutions. They created a product that lets providers query their own data sets to advance analytics and to enroll people in their own studies and clinical trials; that product has solid product-market fit. People like it. It gives us another connection point with providers, another reason for them to share data with us, another reason to be on our platform. That two-way exchange of data — people sending us their clinical data, us generating molecular insight, us returning that insight to providers — sits at the core of how we build these very large data sets, which in total now stand at roughly 40 million patients or so. It has become an enormous data set.

Subbu Nambi

analyst
#11

Hi, everyone. Thanks for letting me ask. I've got a question about the model, plus one about the longer term. On the model side, can you walk us back through what's assumed for gross margin and ASP gains in the event that MolDx xM reimbursement comes through before year-end? And if that isn't assumed, could you size the potential upside? On the longer term, once you turn EBITDA positive, you mentioned wanting to put money back into the business. I'm curious what you're focused on now that offers the best ROI in 2025, and whether that list shifts at all because you've crossed into profitability? Thanks.

Jim Rogers

executive
#12

Yeah. I'll handle the first one, and then Eric can field the second. On ASP progression, we clearly had roughly a $60 lift in oncology ASPs during Q1, mostly driven by moving our xT volume to the ADLT version — the FDA-approved version of that assay — which carries a higher Medicare ASP. Some ASP gains on our liquid biopsy code contributed a minor effect too. As for how things advance across the rest of the year, we noted that by the close of Q1, roughly 20% of xT volume would have shifted to the FDA-approved version. That's basically where it landed. We'll keep migrating additional volume through the remainder of the year, aiming for around 40% by year-end. Most of the ASP gains for the rest of the year come simply from shifting xT volume from AD LT to the FDA-approved version. No xM reimbursements have been assumed. Our first CRC xM went to MolDX in January. That process is still unfolding, and we wouldn't expect anything until later in the year; none of that has been factored into the ASPs.

Eric Lefkofsky

executive
#13

When we think about EBITDA, investments, and ROI, one thing has always mattered a great deal to us, and we've said this before: reaching EBITDA positivity by the time we hit 10, which happens this year. This year we hit 10. Our guidance calls for adjusted EBITDA positivity this year, and I believe we're on track for that, which marks a major milestone, particularly since other businesses that are older than ours, in similar positions, continue to lose between $100 million and $100 million annually. It feels really good that we have these fast growth rates, frequently growth that's best-in-class, and a business generating substantial gross profit and substantial leverage. Running it in a manner that's EBITDA positive, adjusted EBITDA positive, is something we can do. What matters for us, I believe, is that when you consider the opportunity to bring AI to healthcare at scale, it isn't small. Trying to maximize each dollar of profit while sacrificing long-term sustained growth, underinvesting in the process, and then missing what may be among the biggest technology opportunities ever is not what you want. That's on our minds. Specifically, there are numerous areas to put money into across both of our main businesses; in genomics, for instance, the MRD space is incredibly exciting; we have a tumor naive platform we have faith in. Studies across various disease areas are underway. We keep doing those. Those investments are happening now. We did them last year; more will come going forward. Those investments feel good to us, though it's definitely an area where money can go. As for the rest, building out our core AI applications and product set, which includes the foundation model behind much of this, you're always putting money into data and compute, and those aren't cheap. We invest a lot. Again, we did it last year; we do it this year. We'll do it next year. Plenty of investment goes into data and compute so we can bring AI to diagnostics at scale. It's fortunate that the landscape ahead of us is open. There's a lot we'd love to put money into. We're disciplined too, in that we won't get ahead of our skis and will ensure we invest appropriately. I consider us lucky that all of this is converging in a really nice way, with growth generating plenty of extra dollars we can invest to fuel future growth.

Dan Brennan

analyst
#14

Thanks. For my first one, I was hoping you might address genomics volumes. Could you give us a feel for the competitive chatter regarding weather-related disruptions during Q1? The 20% figure landed near the bottom of the range. I'm curious how the quarter unfolded relative to expectations, and how you see volumes shaping up for the balance of the year. Then second, on the insights business, the upfront detail on the Astra deal was really useful. There's some curiosity out there. What more can you share regarding how that unit is performing, and what the pipeline looks like? Any qualitative commentary on demand trends within your insights business would help.

Eric Lefkofsky

executive
#15

Sure. I'll handle the first one. Weather — I'm not sure. I suppose weather may have had certain effects. We definitely had plenty of days where FedEx shipments ran late, or sections of the country were closed for business. We don't devote much energy to that, since we don't view ourselves as merely a lab. That isn't the entirety of what we do. We're somewhat narrowly fixated on it; we regard 20% growth, considering our scale, considering our volume, considering how many tests we run, as fairly remarkable. If you examine Tempus's unit growth overall, I believe we completed roughly 158,000 tests during this quarter. Whenever you have something producing 158,000 billable orders, with units expanding not just by double digits but within the 20%+ bracket, that's quite strong. Our attention is far more on durable long-term expansion than on near-term expansion. If we were ever faced with a choice between growing at 20% across six or eight quarters or ten quarters, versus 22% or 23% during a single quarter, we'd pick the first option every time.

Jim Rogers

executive
#16

Yeah. Turning to your second question, Dan, about the insights business plus the data and services business, that's also gotten off to a strong start. Like we said, the entire data and services business is up more than 40%, while the insights business is up 58%; we were quite lucky as we entered the year. We had $940 million in contract value still left to deliver. Fulfilling those subscriptions and then bringing in more deals during Q1, clearly the standout being April with the AZ, which drives total remaining contract value past a billion dollars for the first time in history. That forward-looking visibility from those contracts lets us feel very confident about the data number for the rest of the year and into the coming several years.

Mark Massaro

analyst
#17

Hey, everyone. Thanks for letting me ask. My first one is for you, Eric. I'm just wondering whether you could describe how you believe you can build on your edge in data and your pharma partnerships to extend some of that early momentum you've had in MRD. Could you also talk about how you view the tumor-naive opportunity, and on top of that, how the tumor-informed opportunity fits together with your partner? Then my second question: could you discuss any pluses and minuses across the wider set of tests in your portfolio that may be gaining share in the market? Thanks.

Eric Lefkofsky

executive
#18

Yeah. Let's take the first one. So, I mean, when you take the long view — and this is something we've been repeating for quite a while now — we see AI and technology as the primary differentiator in diagnostics. That's a little awkward, honestly, because on the diagnostics side we pour so much of our effort into discussing sensitivity and specificity, limited detection, this particular study, that particular test, 500 genes here, 1,000 genes there. What we truly believe is that none of that is what makes you stand out. There's a shift that's been underway for a very long time, one in which sequencing keeps getting cheaper. My hunch is that down the road, every one of us will be running whole genome, whole transcriptome, and similar things on a pretty routine basis. This is what bioinformatics will look like down the road. The real differentiator with these tests isn't the data itself — it's the insights you can pull out for a doctor or a patient from that huge volume of information. And that, in my view, is exactly where Tempus stands apart. Still, we don't really devote much airtime to discussing it, and that's okay, since you'd rather let the results speak when they appear. Consider the foundation model we're developing: essentially, it takes in a massive quantity of data — hundreds of PB — and hunts for links between enormous sets of molecular information that we never could examine before, tied to enormous sets of outcomes. What we'll probably uncover are connections nobody previously realized were there. Take someone diagnosed with non-small cell lung cancer: an NCC guideline's initial recommendation would be testing to determine EGFR positivity. Should the result come back as an EGFR mutation, treatment with an EGFR inhibitor is indicated. Here's the problem—only around fifty percent of those receiving the medication see a response. The remaining fifty percent don't. And within the group that does respond, outcomes vary. One person could stay on the therapy for twelve months. Another could remain on it for ten years; right now we lack any method to sort those individuals into groups. With cancer, what matters most is getting deeper understanding sooner in the journey. My guess is that AI along with technology will deliver that. I'm hoping Tempus is the one, even if a company much like Tempus will ultimately determine, before a patient ever takes an EGFR inhibitor, whether they'll respond to it. Once you have that kind of information, you're able to create truly intelligent, personalized diagnostics; the same holds true for picking treatments. The same holds true for hereditary. The same holds true for MRD. We're going to understand at much finer resolution, not merely whether someone might recur, which these assays excel at detecting relapse well before a scan, but additionally the way to step in. What is the significance when we observe these patterns, whether those patterns are methylomic or simply pieces of mutations circulating in blood, what is the significance? In what way do we interpret them? Will this person probably experience a quite severe recurrence? Will it be gentle? Are we working with a brief period, an extended period? What level of aggressiveness is appropriate? I believe every one of these understandings will be driven by data. My guess is that for our tumor-naive along with tumor-informed offerings, we improve them and ultimately, in my view, render them entirely distinct from everything else available because of what we've put into AI t echnology and the information we've managed to gather, which nobody else simply possesses.

Jim Rogers

executive
#19

When it comes to how our various products currently on the market performed, I would say we experienced an increase throughout the whole portfolio. Naturally, with MRD, we are still somewhat controlling the amount of testing because reimbursement isn't available. We would not expect a huge rise in volumes there, simply due to the fact that without reimbursement, the expense of conducting those tests falls on us. The core assays were all doing well during the quarter.

Michael Ryskin

analyst
#20

Thanks, and good to get the chance to ask something. I'll keep it to a single question, though it may have a few components. I want to connect what you said earlier about Pathos with how Ambry did during the quarter. Specifically, what assumptions are baked into your updated full-year revenue outlook of $1.25 billion? You've lifted that figure by $10 million compared with the previous guidance. Is Pathos's contribution part of that number? It sounds like it is. And if you were to take that $200 million and spread it across 12 quarters, how much of it shows up in this guidance? One more thing: earlier you mentioned Ambry growing in the high teens, while the legacy Tempus business was around 30%. Does that still hold? I just want to break down what's driving the change in guidance. Thanks.

Eric Lefkofsky

executive
#21

Sure. Either Jim or I can address that. The guidance does include some revenue from the new Pathos AZ. At the start of every year, our visibility into revenue is pretty solid, especially when it comes to the data side, although it's not entirely comprehensive. We consistently anticipate booking some revenue that we'll both sign and deliver within the year; that's been true for quite a while; luckily, here we are in, whatever, May, and we're well ahead of where we expected, which is great; this will build gradually. Obviously, we've only got a partial year regardless. We'd always intended to secure some extra revenue; we believe this is the right call. We're also being, I'd say, suitably cautious regarding Ambry and its growth rates and how it does over the rest of the year. Might there be some upside there? Absolutely. Right now, our task is essentially to say, "Hey, this seems like the right spot to be." Incidentally, we're pleased that we raised, by the way, we lifted guidance last quarter by $10 million. We've just lifted it once more by $10 million. We're roughly $20 million above where we stood, I don't know, 90 days ago; we think we're positioned correctly, but we don't want to overreach.

Rachel Vatnsdal

analyst
#22

Hi there, good afternoon. I appreciate you all taking my questions. I'd like to explore the data portion of the portfolio and, more specifically, what you're observing regarding TCV. Considering the macro picture we've been seeing, there's plenty of noise surrounding biotech funding, plus pharma, possible tariffs, and all of that too. Could you discuss the risk you perceive, with this more turbulent macro backdrop, that some of the TCV might get canceled or removed from the backlog? We've also heard certain CROs mention higher cancellation levels in both preclinical and clinical studies. I'm curious how you're evaluating that risk and whether any effect has shown up yet?

Jim Rogers

executive
#23

Yes; a quick note about the data business — we essentially serve two categories of customers. Our work covers 19 of the 20 biggest pharma firms, plus a few hundred biotechs. Clearly, most of the TCV and revenue derives from the large pharma firms, which possess bigger R&D budgets, yet we do engage with quite a few biotechs. On the biotech side, for sure, there's been some effect across the last, let's say, 24 months from the shortage of funding and how that has flowed through. Once more, that accounts for a lesser share of our total business. Big pharma relationships are usually multi-year subscriptions that are committed; we provide the data they've agreed to license across those terms; we haven't observed a meaningful effect on the large pharma side. I'd add too that whenever budgets get slashed or reduced, we actually notice a slight advantage for the data business, since using the kinds of data we license to people lets them design their trials more effectively or pinpoint targets more efficiently. We truly do see a small upside on the data side when budgets shrink, because they can use our data, become more efficient, and sort of make those dollars go further. That's what we've observed in the market.

Dan Arias

analyst
#24

Hey everyone. Here's what we've got. Eric, regarding MRD, clearly there's a ton happening there. If I'm not mistaken, you're approaching a full 12 months of having the xM assay available commercially. Within your program, what has unfolded as you anticipated? And what has caught you off guard a little? Looking ahead across the coming 12 months, what would you point to as the crucial items that would make you feel things are on course and going well?

Eric Lefkofsky

executive
#25

Okay, so to give everyone some context about what we have in our portfolio, it covers our tumor-naive test for colorectal cancer, as well as Personalis' tumor-informed test for non-small cell lung, breast, and IO response. We essentially lead the market in four areas—four really significant areas. We're controlling and limiting the volume of tests we run because right now, MolDX doesn't reimburse any of these assays. Neither ours nor theirs. We're performing these tests without getting paid. So we are carefully managing the volume. If we didn't, we could lose a lot of money. I'd say demand has been very robust; we've been happily surprised by the huge amount of interest in both products. I believe there's room for both naive and informed approaches. Right now, informed is clearly ahead because it offers better sensitivity and specificity. It also has lower limits of detection. Natera has done an excellent job building the market. Informed is sort of the more standard way people view MRD these days. We're lucky that Personalis' platform is truly top-tier on many of those measures, since it's based on whole genome rather than whole exome. I think there's a desire for it, and I'd expect the volumes to be very high once we remove the restrictions. As for tumor-naive, we're all putting in a lot of effort—both us and others with those products—to keep enhancing those assays and ensure they work well. I believe they work quite well right now. Ours definitely does. It does very well, particularly when there isn't extra tissue available, when you can't rerun a whole genome tumor-informed assay because there simply isn't any tissue left. In some cases, like non-small cell lung cancer, where there's already limited tissue, I think those products will do very well. I'd say it's still early, but things are progressing very smoothly, and I haven't been negatively surprised in any major way; it's always like when you launch a new product, you find out all sorts of things. So far, I think we feel really good about our long-term position in MRD.

Liz Krutoholow

executive
#26

We appreciate everyone being here with us right now. As we always do, we're around to answer anything you want to ask afterward. We can't wait to share our next update with you when the following quarter comes around.

Operator

operator
#27

Everyone, that brings us to the end of today's session. Thanks to each of you for being with us. You can go ahead and disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Tempus AI, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Tempus AI, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Tempus AI, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.